Researchers reversed Alzheimer's symptoms in mice using a synthetic peptide, PHDP5, that targets brain function. The study shows that PHDP5 can cross the blood-brain barrier and restore memory by improving synaptic function. The treatment could delay cognitive decline if administered early. This breakthrough paves the way for new Alzheimer's therapies focusing on brain structure and function.
